News Stocks Omkar Pharmachem Limited Clarifies Delayed Filing for Independent Director CessationOmkar Pharmachem Limited Clarifies Delayed Filing for Independent Director Cessation
Omkar Pharmachem Limited clarified to BSE Limited the delayed filing of an announcement regarding Mr. Janak Raj Sharma's cessation as Independent Director on 12th February, 2026, after completing two consecutive five-year terms. The company filed the announcement on 14th February, 2026, citing their understanding that such matters should be taken on record by the Board first. The company regretted the inadvertent delay and requested acceptance of their clarification as regulatory compliance.
*this image is generated using AI for illustrative purposes only.
Omkar Pharmachem Limited has provided a detailed clarification to BSE Limited regarding the delayed filing of a corporate announcement concerning the cessation of an independent director under SEBI regulations. The clarification, submitted on 16th February, 2026, addresses procedural aspects of regulatory compliance and board governance.
Director Cessation Details
The company confirmed that Mr. Janak Raj Sharma (DIN: 07420418) completed his tenure as an Independent Director with effect from 12th February, 2026. His departure marks the completion of two consecutive terms of five years each in his capacity as an independent director of the company.
| Parameter: | Details |
|---|---|
| Director Name: | Mr. Janak Raj Sharma |
| DIN: | 07420418 |
| Position: | Independent Director |
| Cessation Date: | 12th February, 2026 |
| Tenure Completed: | Two consecutive terms of five years each |
Filing Delay and Regulatory Compliance
The corporate announcement regarding the director's cessation was filed on 14th February, 2026, instead of within the mandatory 24-hour period from 12th February, 2026, as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company acknowledged this delay in their clarification to the stock exchange.
Omkar Pharmachem explained their procedural understanding that led to the delayed filing. The company believed that intimations pertaining to the cessation of an Independent Director should be filed under Regulation 30 read with Schedule III, Part A, only after the matter is formally taken on record by the Board of Directors.
Board Meeting and Procedural Clarification
Following this understanding, the matter was placed before the Board and noted during the Board Meeting held on 14th February, 2026. The corporate announcement was subsequently filed on the same date after board approval. The clarification was signed by Managing Director Bhawani Shankar Goyal (DIN: 03255804) on behalf of the company.
The company expressed regret for the inadvertent delay and requested BSE to accept their clarification as compliance with the applicable provisions of the SEBI (LODR) Regulations, 2015. This clarification demonstrates the company's commitment to regulatory compliance and transparent communication with stakeholders regarding board composition changes.
17
